Logo image of TRDA

ENTRADA THERAPEUTICS INC (TRDA) Stock Fundamental Analysis

NASDAQ:TRDA - US29384C1080 - Common Stock

5.405 USD
+0.19 (+3.54%)
Last: 9/5/2025, 2:29:07 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TRDA. TRDA was compared to 542 industry peers in the Biotechnology industry. TRDA has a great financial health rating, but its profitability evaluates not so good. TRDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TRDA had negative earnings in the past year.
TRDA had a negative operating cash flow in the past year.
In the past 5 years TRDA reported 4 times negative net income.
TRDA had negative operating cash flow in 4 of the past 5 years.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

The Return On Assets of TRDA (-16.34%) is better than 80.07% of its industry peers.
The Return On Equity of TRDA (-19.33%) is better than 84.69% of its industry peers.
Industry RankSector Rank
ROA -16.34%
ROE -19.33%
ROIC N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

7

2. Health

2.1 Basic Checks

TRDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRDA has more shares outstanding
The number of shares outstanding for TRDA has been increased compared to 5 years ago.
There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

TRDA has an Altman-Z score of 1.53. This is a bad value and indicates that TRDA is not financially healthy and even has some risk of bankruptcy.
TRDA has a better Altman-Z score (1.53) than 66.05% of its industry peers.
There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.53
ROIC/WACCN/A
WACC9.85%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

TRDA has a Current Ratio of 18.64. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 18.64, TRDA belongs to the top of the industry, outperforming 93.17% of the companies in the same industry.
A Quick Ratio of 18.64 indicates that TRDA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 18.64, TRDA belongs to the top of the industry, outperforming 93.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.64
Quick Ratio 18.64
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

TRDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -160.14%.
Looking at the last year, TRDA shows a very negative growth in Revenue. The Revenue has decreased by -66.80% in the last year.
EPS 1Y (TTM)-160.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-167.1%
Revenue 1Y (TTM)-66.8%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-97.94%

3.2 Future

Based on estimates for the next years, TRDA will show a very strong growth in Earnings Per Share. The EPS will grow by 34.13% on average per year.
Based on estimates for the next years, TRDA will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-288.51%
EPS Next 2Y-110.6%
EPS Next 3Y-61.65%
EPS Next 5Y34.13%
Revenue Next Year-79.32%
Revenue Next 2Y-57.53%
Revenue Next 3Y-32.87%
Revenue Next 5Y-14.87%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2030 50M 100M 150M 200M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TRDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TRDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

A cheap valuation may be justified as TRDA's earnings are expected to decrease with -61.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-110.6%
EPS Next 3Y-61.65%

More info and screens

0

5. Dividend

5.1 Amount

TRDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (9/5/2025, 2:29:07 PM)

5.405

+0.19 (+3.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners78.38%
Inst Owner Change-10.42%
Ins Owners0.79%
Ins Owner Change3.37%
Market Cap205.61M
Analysts84
Price Target18.87 (249.12%)
Short Float %3.28%
Short Ratio5.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.75%
Min EPS beat(2)-20.31%
Max EPS beat(2)47.81%
EPS beat(4)3
Avg EPS beat(4)46.19%
Min EPS beat(4)-20.31%
Max EPS beat(4)104.39%
EPS beat(8)6
Avg EPS beat(8)188.96%
EPS beat(12)7
Avg EPS beat(12)115.22%
EPS beat(16)8
Avg EPS beat(16)25.57%
Revenue beat(2)1
Avg Revenue beat(2)8.99%
Min Revenue beat(2)-80.19%
Max Revenue beat(2)98.17%
Revenue beat(4)3
Avg Revenue beat(4)63.29%
Min Revenue beat(4)-80.19%
Max Revenue beat(4)179.44%
Revenue beat(8)7
Avg Revenue beat(8)132.7%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.76%
PT rev (3m)-23.97%
EPS NQ rev (1m)-9.97%
EPS NQ rev (3m)-28.62%
EPS NY rev (1m)-11.62%
EPS NY rev (3m)-9.09%
Revenue NQ rev (1m)-3.89%
Revenue NQ rev (3m)-26.59%
Revenue NY rev (1m)-17.55%
Revenue NY rev (3m)-2.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.59
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-4.65
Fwd EYN/A
FCF(TTM)-3.33
FCFYN/A
OCF(TTM)-3.26
OCFYN/A
SpS2.09
BVpS9.98
TBVpS9.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.34%
ROE -19.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.89%
Cap/Sales 3.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.64
Quick Ratio 18.64
Altman-Z 1.53
F-Score2
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)144.47%
Cap/Depr(5y)309.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-167.1%
EPS Next Y-288.51%
EPS Next 2Y-110.6%
EPS Next 3Y-61.65%
EPS Next 5Y34.13%
Revenue 1Y (TTM)-66.8%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-97.94%
Revenue Next Year-79.32%
Revenue Next 2Y-57.53%
Revenue Next 3Y-32.87%
Revenue Next 5Y-14.87%
EBIT growth 1Y-202.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-736.79%
EBIT Next 3Y-107.2%
EBIT Next 5YN/A
FCF growth 1Y-216.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-209.13%
OCF growth 3YN/A
OCF growth 5YN/A